Summary
(±)CP-96,345, a nonpeptide and highly selective NK-1 receptor antagonist, was tested acutely and chronically as an inhibitor of the cardiovascular responses induced by the intrathecal (i.t.) injection of substance P (SP) and neuropeptide K (NPK) in the conscious rat. When given at T-9 spinal cord level, NPK (0.65, 3.25 and 6.5 nmol) and SP (6.5, 16.25 and 32.5 nmol) produced increases in mean arterial pressure and heart rate. The cardiovascular responses to NPK were greater in intensity and duration than those produced by SP. The prior i.t. injection of (±)CP-96,345 (0.65 and 6.5 nmol, 15 min earlier) inhibited in a dose-dependent manner the pressor response and the tachycardia induced by 6.5 nmol SP while 65 nmol of the antagonist was required to reduce the effects of 3.25 nmol NPK. However, both the SP and NPK-induced cardiovascular changes were blocked 2 days after the Lt. injection of 6.5 nmol (±)CP-96,345. Five days after a single i.t. injection of 6.5 nmol (±)CP-96,345, the cardiovascular response to SP remained unaffected while that of NPK was partially attenuated. Moreover, (±)CP-96,345 was active as an antagonist when given ix. at the dose of 0.13 mg/kg. Conversely, (±)CP-96,345 failed to block the cardiovascular effect caused by the i.t. injection of 81 pmol bradykinin and did not produce any changes on resting blood pressure and heart rate when given alone either i.t. or L v. The results indicate that (±)CP-96,345 is a specific and long-acting antagonist which crosses the blood-brain barrier to block the action of SP and NPK in the spinal cord. Furthermore, these findings are consistent with the hypothesis that receptors of the NK-1 subtype mediate the cardiovascular responses evoked by the spinal action of neurokinins.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beresford IJM, Birch PJ, Hagan RM, Ireland SJ (1991) Investigation into species variants in tachykinin NK1 receptors by use of the nonpeptide antagonist, CP-96,345. Br J Pharmacol 104:292–293
Boyle SJ, Howson W, McKnight AT (1991) An examination of the selectivity of a new non-peptide tachykinin antagonist. Br J Pharmacol 104:146P
Buck SH, Burcher E (1986) The tachykinins: a family of peptides with a brood of receptors. Trends Pharmacol Sci 7:65–68
Constantine JW, Lebel WS, Woody HA (1991) Inhibition of tachykinininduced hypotension in dogs by CP-96,345, a selective blocker of NK-1 receptors. Naunyn-Schmiedeberg's Arch Pharmacol 344:471–477
Couture R, Yashpal K, Henry JL, Escher E, Regoli D (1985) Characterization of spinal actions of four substance P analogues. Eur J Pharmacol 110:63–69
Couture R, Gupta A, Kérouac R, Escher E, Regoli D (1987) Spinal actions of substance P analogues on cardiovascular responses in the rat: a structure-activity analysis. Can J Physiol Pharmacol 65:412–418
Couture R, Laneuville O, Guimond C, Drapeau G, Regoli D (1989) Characterization of the peripheral action of neurokinins and neurokinin receptor selective agonists on the rat cardiovascular system. Naunyn-Schmiedeberg's Arch Pharmacol 340:547–557
Davis BM, Krause JE, McKelvy JF, Cabot JB (1984) Effects of spinal lesions on substance P levels in the rat sympathetic preganglionic cell column: evidence for local spinal regulation. Neuroscience 13:1311–1326
Décarie A, Couture R (1992) Characterization of the peripheral action of neuropeptide K on the rat cardiovascular system. Eur J Pharmacol 213:125–131
Gitter BD, Waters DC, Bruns RF, Mason NR, Nixon JA, Howbert JJ (1991) Species differences in affinities of non-peptide antagonists for substance P receptors. Eur J Pharmacol 197:237–238
Guard S, Watson SP (1991)Tachykinin receptor types: classification and membrane signalling mechanisms. Neurochem Int 18:149–165
Hasséssian H, Drapeau G, Couture R (1988) Spinal action of neurokinins producing cardiovascular responses in the conscious freely moving rat: evidence for a NK-1 receptor mechanism. Naunyn-Schmiedeberg's Arch Pharmacol 338:649–654
Hasséssian H, Couture R, de Champlain J (1990) Sympathoadrenal mechanisms underlying cardiovascular responses to intrathecal substance P in conscious rats. J Cardiovasc Pharmacol 15:736–744
Helke CJ, Charlton GG, Keeler JR (1985) Bulbospinal substance P and sympathetic regulation of the cardiovascular system: A review. Peptides 6 [Suppl 2]:69–74
Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ (1990) Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J 4:1606–1615
Hua XY, Theodorsson-Norheim E, Brodin E, Lundberg JM, Hokfelt T (1985) Multiple tachykinins (neurokinin A, neuropeptide K and substance P) in capsaicin-sensitive sensory neurons in the guinea pig. Regul Peptides 13:1–19
Jacques L, Couture R, Drapeau G, Regoli D (1989) Capillary permeability induced by intravenous neurokinins: receptor characterization and mechanism of action. Naunyn-Schmiedeberg's Arch Pharmacol 340:170–179
Lopes P, Couture R (1992) Cardiovascular responses elicited by intrathecal kinins in the conscious rat. Eur J Pharmacol 210:137–147
Lundberg JM, Hokfelt T (1983) Coexistence of peptides and classical neurontransmitters. Trends Neurosci 6:325–333
McLean S, Ganong AH, Seeger TF, Bryce DK, Pratt KG, Reynolds LS, Siok CJ, Lowe III JA, Heym J (1991) Activity and distribution of binding sites in brain of a nonpeptide substance P (NKI) receptor antagonist. Science 251:437–439
Pham TM, Couture R (1991) Role for neuropeptide K (NPK) in the spinal regulation of the cardiovascular system. Third IBRO World Congress of Neuroscience, Montreal, Canada, August 4–9, 1991. Abstract P 19.3
Quirion R, Dam TV (1988) Multiple neurokinin receptors: recent developments. Regul Pept 22:18–25
Regoli D, Drapeau G, Dion S, Couture R (1988) New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol Sci 9:290–295
Rouissi N, Gitter BD, Waters DC, Howbert JJ, Nixon JA, Regoli D (1991) Selectivity and specificity of new, non-peptide, quinuclidine antagonists of substance P. Biochem Biophys Res Commun 176:894–901
Schmidt AW, McLean S, Heym J (1992) The substance P receptor antagonist CP-96,345 interacts with Cat' channels. Eur J Pharmacol 215:351–352
Snider MR, Constantine JW, Lowe III JA, Longo KP, Lebel WS, Woody HA, Drozda SE, Desai MC, Vinick FJ, Spencer RW Hess H-J (1991a) A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 251:435–437
Snider MR, Longo KP, Drozda SE, Lowe III JA, Leeman SE (1991b) Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation in rats. Proc Natl Acad Sci USA 88:10042–10044
Takeda Y, Krause JE (1989) Neuropeptide K potently stimulates salivary gland secretion and potentiates substance P-induced salivation. Proc Natl Acad Sci USA 86:392–396
Vaught JL (1988) Substance P antagonists and analgesia: a review of the hypothesis. Life Sci 43:1419–1431
Author information
Authors and Affiliations
Additional information
Correspondence to R. Couture at the above address
Rights and permissions
About this article
Cite this article
Pham, T.M., Couture, R. Inhibitory action of (±)CP-96,345 on the cardiovascular responses to intrathecal substance P and neuropeptide K in the conscious freely moving rat. Naunyn-Schmiedeberg's Arch Pharmacol 347, 34–41 (1993). https://doi.org/10.1007/BF00168769
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00168769